Tr3-specific binding agents and methods for their use

Details Tr3-specific binding agents and methods for their use Tr3-specific binding agents and methods for their use

2006-02-07

2006-02-07

Andres, Janet (Department: 1646)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S007210, C435S007230, C435S007240, C530S387100, C530S388100, C530S389100, C514S002600

Reexamination Certificate

active

06994976

ABSTRACT:
Biologically active TR3-specific binding agents and methods for their use are disclosed. The biologically active TR3-specific binding agents are useful for inhibiting the proliferation of cells expressing TR3. These biologically active agents are particularly useful for treating T-cell mediated diseases such as graft-versus-host disease, organ rejection, tumor growth, autoimmunity, and inflammation.

REFERENCES:
patent: 6462176 (2002-10-01), Ashkenazi
patent: WO 97 33904 (1997-09-01), None
patent: WO 97 37020 (1997-10-01), None
patent: WO 98 05783 (1998-02-01), None
patent: WO 99/19490 (1999-04-01), None
patent: WO 00 64465 (2000-11-01), None
Screaton, G. et al. Proc. Nat. Acad. Sci. 1997, vol. 94, pp. 4615-1619.
Chicheportiche, Y., et al., “TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly inducus apoptosis” (1997)J. Bio Chem.272(51): 32401-32410.
Chicheportiche, Y., et al., “Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies” (2002)Arthritis Res.4(2): 126-133.
Donohue, P.J., et al., “TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity” (2003)Arterioscler. Thromb Vasc. Biol.23(4): 594-600.
Kaplan, M.J., et al., “TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand)mediate CD4+T cell killing of antigen-presenting macrophages”J. Immunol164(6): 2897-2904.
Kaptein, A., et al., “Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3)” (2000)FEBS lett.485(2-3): 135-141.
Marsters, S. A., et al., “Identification of a ligand for the death-domain-containing receptor Apo3” (1998)Curr Biol.8(9): 525-528.
Nakayama, M., et al., “Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies” (2003)Biochem Biophys Res Commun306(4): 819-825.
Polek., et al. “TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TWEAKR. Evidence for a second TWEAK receptor” (2003)J. Bio Chem.
Schneider, P., et al., “TWEAK can induce cell death via endogenous TNF and TNF receptor 1” (1999)Eur J Immunol29(6): 1785-1792.
Wiley, S.R., et al., “A novel TNF receptor family member binds TWEAK and its implicated in angiogenesis” (2001)Immunity15(5): 837-846.
International Search Report dated May 10, 2001.

Affiliated with

Also associated with

Rating

Tr3-specific binding agents and methods for their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tr3-specific binding agents and methods for their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tr3-specific binding agents and methods for their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3707974